{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Shot+Blocker", "query": { "intervention": "Shot Blocker" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 20, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Shot+Blocker&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T18:02:38.218Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04918147", "title": "Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "IgG4 Related Disease", "IgG4-RD" ], "interventions": [ { "name": "elotuzumab", "type": "DRUG" }, { "name": "placebo for elotuzumab", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "diphenhydramine", "type": "DRUG" }, { "name": "acetaminophen", "type": "DRUG" }, { "name": "famotidine", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 8, "start_date": "2021-10-13", "completion_date": "2024-01-04", "has_results": true, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-09-06T18:02:38.218Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04918147" }, { "nct_id": "NCT00799604", "title": "Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "clevidipine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Medicines Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2008-11", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2014-08-29", "last_synced_at": "2026-09-06T18:02:38.218Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00799604" }, { "nct_id": "NCT03689946", "title": "Effect of Evolocumab on Coronary Atherosclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cardiovascular Disease", "Hyperlipidemia" ], "interventions": [ { "name": "Evolocumab", "type": "DRUG" }, { "name": "18F-NaF PET", "type": "DIAGNOSTIC_TEST" }, { "name": "CCTA", "type": "DIAGNOSTIC_TEST" }, { "name": "Omnipaque", "type": "DRUG" }, { "name": "Metoprolol", "type": "DRUG" }, { "name": "Nitroglycerin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2019-03-19", "completion_date": "2023-05-30", "has_results": true, "last_update_posted_date": "2024-07-17", "last_synced_at": "2026-09-06T18:02:38.218Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03689946" }, { "nct_id": "NCT04840615", "title": "Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mesothelioma" ], "interventions": [ { "name": "LMB-100", "type": "BIOLOGICAL" }, { "name": "ipilimumab", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "FDG-PET", "type": "DIAGNOSTIC_TEST" }, { "name": "CT CAP", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "Echocardiogram", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 2, "start_date": "2021-06-11", "completion_date": "2022-01-12", "has_results": true, "last_update_posted_date": "2024-02-02", "last_synced_at": "2026-09-06T18:02:38.218Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04840615" }, { "nct_id": "NCT06867068", "title": "Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anesthesia", "Tooth Extraction" ], "interventions": [ { "name": "Midazolam Hydrochloride", "type": "DRUG" }, { "name": "Fentanyl", "type": "DRUG" }, { "name": "Ketamine", "type": "DRUG" }, { "name": "Propofol injection", "type": "DRUG" }, { "name": "Nitrous oxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Albert Einstein College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 73, "start_date": "2016-10-04", "completion_date": "2024-06-10", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-09-06T18:02:38.218Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06867068" }, { "nct_id": "NCT00910689", "title": "Drug and Non-Drug Treatment Of Severe Migraine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Migraine Headache" ], "interventions": [ { "name": "Propranolol or nadolol", "type": "DRUG" }, { "name": "Placebo control", "type": "DRUG" }, { "name": "Behavioral Migraine Management (BMM)", "type": "BEHAVIORAL" }, { "name": "Optimal Acute Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Ohio University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 232, "start_date": "2001-07", "completion_date": "2005-11", "has_results": true, "last_update_posted_date": "2016-11-22", "last_synced_at": "2026-09-06T18:02:38.218Z", "location_count": 2, "location_summary": "Athens, Ohio • Westerville, Ohio", "locations": [ { "city": "Athens", "state": "Ohio" }, { "city": "Westerville", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00910689" }, { "nct_id": "NCT05748834", "title": "Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Tucatinib", "type": "DRUG" }, { "name": "Doxil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2023-07-24", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-09-06T18:02:38.218Z", "location_count": 8, "location_summary": "Columbia, Maryland • Bensalem, Pennsylvania • Nashville, Tennessee + 4 more", "locations": [ { "city": "Columbia", "state": "Maryland" }, { "city": "Bensalem", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05748834" }, { "nct_id": "NCT01242488", "title": "Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "CDP6038", "type": "BIOLOGICAL" }, { "name": "Tocilizumab (Actemra or RoActemra)", "type": "BIOLOGICAL" }, { "name": "Placebo sc", "type": "OTHER" }, { "name": "Placebo iv", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 221, "start_date": "2010-11", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2024-07-17", "last_synced_at": "2026-09-06T18:02:38.218Z", "location_count": 74, "location_summary": "Mesa, Arizona • Paradise Valley, Arizona • Scottsdale, Arizona + 66 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01242488" }, { "nct_id": "NCT01365455", "title": "Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Severe Plaque-type Psoriasis" ], "interventions": [ { "name": "secukinumab 150 mg", "type": "DRUG" }, { "name": "placebo to secukinumab 150 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 738, "start_date": "2011-06", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-09-06T18:02:38.218Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01365455" }, { "nct_id": "NCT01482221", "title": "A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "AZD6765 iv", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 542, "start_date": "2011-12-16", "completion_date": "2013-08-26", "has_results": true, "last_update_posted_date": "2017-04-11", "last_synced_at": "2026-09-06T18:02:38.218Z", "location_count": 33, "location_summary": "Chino, California • Lond Beach, California • San Diego, California + 30 more", "locations": [ { "city": "Chino", "state": "California" }, { "city": "Lond Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Heaven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01482221" } ] }